Tadahiro Shoji

Summary

Affiliation: Iwate Medical University
Country: Japan

Publications

  1. pmc A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19 1 Uchimaru, Morioka, 020 8505, Japan
    Cancer Chemother Pharmacol 73:895-901. 2014
  2. ncbi request reprint Efficacy of neoadjuvant chemotherapy followed by radical hysterectomy in locally advanced non-squamous carcinoma of the uterine cervix: a retrospective multicenter study of Tohoku Gynecologic Cancer Unit
    T Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan
    Eur J Gynaecol Oncol 33:353-7. 2012
  3. doi request reprint Tako-Tsubo cardiomyopathy caused immediately following cesarean section delivery of triplets: a case report
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Center for Maternal Fetal Intensive Care Unit, Iwate Medical University School of Medicine, Morioka, Japan
    Gynecol Obstet Invest 74:84-8. 2012
  4. pmc Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents
    Eriko Takatori
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19 1, Uchimaru, Morioka, Iwate, 020 8505, Japan
    J Ovarian Res 5:16. 2012
  5. pmc Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19 1 Uchimaru, Morioka 020 8505, Japan
    Cancer Chemother Pharmacol 71:657-62. 2013
  6. doi request reprint Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study)
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan
    Int J Gynecol Cancer 21:44-50. 2011
  7. ncbi request reprint [Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer]
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine
    Gan To Kagaku Ryoho 37:643-8. 2010
  8. ncbi request reprint A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study
    Yoshihito Yokoyama
    Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki, Japan
    Oncol Rep 19:1551-6. 2008
  9. ncbi request reprint Pilot study of intraperitoneal administration of triamcinolone acetonide for cancerous ascites in patients with end-stage gynecological cancer
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan
    Int J Gynecol Cancer 24:1093-7. 2014
  10. pmc Clinical significance of atypical glandular cells in the Bethesda system 2001: a comparison with the histopathological diagnosis of surgically resected specimens
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan
    Cancer Invest 32:105-9. 2014

Collaborators

Detail Information

Publications21

  1. pmc A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19 1 Uchimaru, Morioka, 020 8505, Japan
    Cancer Chemother Pharmacol 73:895-901. 2014
    ....
  2. ncbi request reprint Efficacy of neoadjuvant chemotherapy followed by radical hysterectomy in locally advanced non-squamous carcinoma of the uterine cervix: a retrospective multicenter study of Tohoku Gynecologic Cancer Unit
    T Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan
    Eur J Gynaecol Oncol 33:353-7. 2012
    ....
  3. doi request reprint Tako-Tsubo cardiomyopathy caused immediately following cesarean section delivery of triplets: a case report
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Center for Maternal Fetal Intensive Care Unit, Iwate Medical University School of Medicine, Morioka, Japan
    Gynecol Obstet Invest 74:84-8. 2012
    ..She was extubated from the ventilator after 3 days of catecholamine, furosemide and carperitide administration. She was discharged from the hospital on day 53 without symptoms...
  4. pmc Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents
    Eriko Takatori
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19 1, Uchimaru, Morioka, Iwate, 020 8505, Japan
    J Ovarian Res 5:16. 2012
    ..abstract:..
  5. pmc Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19 1 Uchimaru, Morioka 020 8505, Japan
    Cancer Chemother Pharmacol 71:657-62. 2013
    ..There are no reports on the use of neoadjuvant chemotherapy (NAC) in non-squamous cell cervical carcinoma. We examined the effectiveness and safety of paclitaxel/carboplatin (TC) and docetaxel/carboplatin (DC)...
  6. doi request reprint Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study)
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan
    Int J Gynecol Cancer 21:44-50. 2011
    ..To evaluate the efficacy and safety of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of patients with recurrent ovarian cancer after previous treatment with platinum and taxane agents...
  7. ncbi request reprint [Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer]
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine
    Gan To Kagaku Ryoho 37:643-8. 2010
    ..We assessed the antitumor response and safety of neoadjuvant chemotherapy (NAC) using cisplatin (CDDP) and irinotecan(CPT-11)given every three weeks for locally advanced cervical cancer with a bulky mass...
  8. ncbi request reprint A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study
    Yoshihito Yokoyama
    Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki, Japan
    Oncol Rep 19:1551-6. 2008
    ..4%) and 1 (2.2%), respectively. These results indicate that weekly nedaplatin of 30 mg/m(2) with concurrent radiotherapy is an effective and well-tolerated regimen for advanced squamous cell carcinoma of the uterine cervix...
  9. ncbi request reprint Pilot study of intraperitoneal administration of triamcinolone acetonide for cancerous ascites in patients with end-stage gynecological cancer
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan
    Int J Gynecol Cancer 24:1093-7. 2014
    ..We intraperitoneally administered triamcinolone acetonide (TA) to patients with end-stage gynecological cancer as a pilot study, and our treatment results are reported herein...
  10. pmc Clinical significance of atypical glandular cells in the Bethesda system 2001: a comparison with the histopathological diagnosis of surgically resected specimens
    Tadahiro Shoji
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan
    Cancer Invest 32:105-9. 2014
    ..We believe that conization or hysterectomy aimed at diagnosis and treatment, as well as endometrial histodiagnosis, should be carried out aggressively in patients with AGC. ..
  11. doi request reprint Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy
    Eriko Takatori
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan
    J Obstet Gynaecol Res 39:1354-8. 2013
    ..The findings in this patient indicate that CPT-11 should be administered with great care, even at a dose of 60 mg/m², in patients receiving combined therapy with CPT-11 and NDP who are compound heterozygous for UGT1A1*6 and UGT1A1*28...
  12. ncbi request reprint Identifying prognostic factors in Japanese women with pseudomyxoma peritonei: a retrospective clinico-pathological study of the Tohoku Gynecologic Cancer Unit
    Takanobu Kojimahara
    Yamagata University School of Medicine, Department of Obstetrics and Gynecology, Yamagata, Japan
    Tohoku J Exp Med 223:91-6. 2011
    ..064). In conclusion, the macroscopic residual tumor is an important prognostic factor in Japanese patients with PMP...
  13. ncbi request reprint A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix
    Eriko Takatori
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Uchimaru 19 1, Morioka, Iwate, 020 8505, Japan
    Int J Clin Oncol 19:336-40. 2014
    ..The efficacy and safety of S-1/oxaliplatin (SOX) therapy in patients with recurrent adenocarcinoma of the uterine cervix were examined in a pilot study...
  14. ncbi request reprint Yolk sac tumor of the ovary: a retrospective multicenter study of 33 Japanese women by Tohoku Gynecologic Cancer Unit (TGCU)
    Takanobu Kojimahara
    Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan
    Tohoku J Exp Med 230:211-7. 2013
    ..Univariate analysis revealed the following significant prognostic factors (P < 0.05): stage, tumor diameter, and residual tumor. Extensive debulking surgery to minimize residual tumor would improve the prognosis. ..
  15. doi request reprint Case of peptide-YY-producing strumal carcinoid of the ovary: a case report and review
    Eriko Takatori
    Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Iwate, Japan
    J Obstet Gynaecol Res 38:1266-70. 2012
    ..The clinical course of this case supports the previously recognized correlation between peptide-YY-producing ovarian carcinoid and constipation...
  16. ncbi request reprint Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer
    Toshio Fujimoto
    Department of Obstetrics and Gynecology, Akita University School of Medicine, 1 1 1 Hondo, Akita 010 8543, Japan
    Gynecol Oncol 107:253-9. 2007
    ..The purpose of this study was to determine whether para-aortic lymphadenectomy improves disease-related survival (DRS) in stage IIIc endometrial cancer...
  17. doi request reprint Triple simultaneous primary invasive gynecological malignancies: a case report
    Eriko Takatori
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan
    J Obstet Gynaecol Res 40:627-31. 2014
    ....
  18. doi request reprint Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial
    Seisuke Kumagai
    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan
    Int J Gynecol Cancer 21:1585-91. 2011
    ....
  19. ncbi request reprint Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells
    Naoko Izutsu
    Department of Pathology, School of Medicine, Iwate Medical University, Morioka, Iwate 020 8505, Japan
    Int J Oncol 32:1227-35. 2008
    ....